TherGelFas · Novel nanometrically structured therapeutic hydrogel as injectable for fascial tissues surrounding the nerves intended for preventive treatment of chronic pain
„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“
- Период
- 2018-11-01 → 2020-10-31
- Финансиране от ЕС
- 170 122 €
- Участници
- 1
- Схема
- MSCA-IF-EF-SE
Линиите свързват координатора с партньорите.
Накратко на български
Наноструктуриран хидрогел на основата на хиалуронова киселина се тества като средство за контролирано освобождаване на лекарства около нервите след операция. Това помага за по-ефективното управление на острата болка, за да се намали рискът тя да се превърне в хронична.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Novel nanometrically structured therapeutic hydrogel as injectable for fascial tissues surrounding the nerves intended for preventive treatment of chronic pain
Worldwide chronic pain conditions are one of the major reasons why people exit the labour market prematurely and it contributes significantly to disability retirement. When acute pain is not properly treated in the first few days, it can become chronic, and the current treatments for chronic pain are costly and not effective. Successful postoperative acute pain treatment is key to avoid pain chronification and associated complications. Thus, it is important to receive adequate pain management from early stages post-surgery. “Fast track” recovery methodologies are multi-disciplinary pain management techniques that combine commonly used medicines against pain in different ways intra-operatively and post-operatively. Nevertheless, current prescription medicines used by this method relieve pain symptoms temporarily but do not prevent chronic pain from the start and have side effects because the drug is not correctly located by the nerves and randomly spreads locally. The main objectives of the project were: to develop, validate and scale-up a novel nanostructured hydrogel-based injectable pharmaceutical product to be applied during and post-surgery in the fascial tissue that protects the nerves where the pain originates and chronifies. To create the proof of concept of a new easy-to-use technology by combining innovation in advanced biomaterials (porous nanostructured hydrogel based on hyaluronic acid) with the ability to load and release drugs to reduce pain in a controlled manner. To address the above, new formulations of hydrogels have been developed, loaded with the active substance, controlled release studies have been performed, and all the procedures have been verificated, validated and scaled-up. Nanometric hydrogels have been included to provide a better control of the drug from the hydrogel matrix, developing a combined system of nanocarriers and macroscopic matrix. The product is a sterile viscoelastic solution of cross-linked sodium hyaluronate (NaHA) indicated for the vehiculization of an anaesthetic substance.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
The key goals of the “TherGeLFas” project are: (a) the training of a talented experienced researcher in the fast growing field of innovative biomaterials for medical applications where the host and partner institutions have a critical knowledge and expertise; and, (b) the design and development of cost- efficient polymer materials in order to develop a new medicinal product for post-operative acute pain treatment and prevention of chronification.The aim of the research project and the main scientific challenge is thereby to develop a ‘therapeutically effective’ hydrogel based injectable product to be applied during and post-surgery in the fascial tissue that protects the nerves where the pain originates and chronifies. TherGelFas expects to create the proof of concept of a new medicinal product by combining advanced materials (a biodegradable, antiseptic and biocompatible carrier, made of porous nanostructured hydrogel based on hyaluronic acid) with the ability to load and release non-steroidal antiinflamatory drugs in a controlled manner. It is aimed for the improvement of the current multimodal strategies of peripheral nerve blockade injections used during and post-surgery in acute pain treatment to prevent it from becoming chronic and that unfortunately are unsuccessful many times. The first achievement will be that of the training of the experienced researcher in new areas of knowledge such as business development from original concept stages to production scale-up, manufacturing and marketing stages. The second achievement will be to scientifically assess whether these hydrogels can improve and replace currently used therapies, to develop a proof-of-concept scalable product. The third achievement will be to learn how to perform correctly the necessary steps needed to launch a product of this kind, such as record and prepare all the documentation needed to present the product to the corresponding regulatory agencies.
Оригинален текст от CORDIS (на английски).
Участници
- I+MED S COOP · VITORIA-GASTEIZКоординаторИспания
Връзки
Данни: CORDIS, © Европейски съюз